Kornimate/medical-research-clean huggingface dataset:
mobile unit screening of pathologies associated with chronic diseases - feasibility

Conditions: Chronic Obstructive Pulmonary Disease; Type II Diabetes; Atherosclerosis

Summary: the main objective of this study is to assess the feasibility of standardized screening for comorbidities among patients with one or more of three chronic diseases (diabetes, copd, atherosclerosis) by a mobile unit at times and localities under-served by health actors.

the investigators secondary objectives include assessing patient and gp satisfaction in relation to the mobile screening team.

Eligibility criteria:
inclusion criteria: * the patient must have given his/her informed and signed consent * the patient must be insured or beneficiary of a health insurance plan * the patient has one or more of the following three diseases: (1) chronic obstructive pulmonary disease (copd); (2) type ii diabetes; (3) atherosclerosis. exclusion criteria: * the patient is participating in another study * the patient is in an exclusion period determined by a previous study * the patient is under judicial protection, under tutorship or curatorship * the patient refuses to sign the consent * it is impossible to correctly inform the patient * there is a need to take urgent therapeutic care in the opinion of the general practitioner * the patient has received within the past year, a full examination including doppler assessment of supra-aortic arteries, abdominal aorta and lower limbs; the patient has received a measure of the ankle-brachial index at the toe.

Keywords: mobile screening team feasibility
project veriovue enhancements - arterial study

Conditions: Diabetes Mellitus

Summary: the aim of this performance evaluation is to compare the blood glucose results obtained using the veriovue blood glucose monitoring system (bgms) with those obtained from a validated comparator method (istat 1 analyser) using arterial blood. the main question the study aims to answer is: how accurate is the veriovue bgms when compared to a product that has already been confirmed as accurate (istat 1 analyser) when hospital staff test arterial blood on these two types of instrument? participants will have a small amount of blood taken from an existing arterial line.

up to two uk nhs hospital sites will be used to collect a minimum of 100 evaluable samples from participants fitted with an arterial line that meet the acceptance criteria. consent will be obtained from the participants prior to taking part in the study. if the participant meets the enrolment criteria then demographics and medical history information will be collected. a small volume of blood (max 150µl) will be collected from an existing arterial line. the blood will then be applied to six investigational onetouch veriovue meters (with expanded haematocrit range 20-65%) fitted with onetouch verio test strips and the blood glucose meter readings recorded. three different lots of test strips will be used in rotation across the study. within 5 minutes of the last meter test, trained staff will use blood from the same sample and perform a test on the istat analyser to obtain the blood glucose, haematocrit and oxygen levels of the sample. no treatment decisions will be made based on the blood glucose results obtained for this study. the study documentation will be reviewed by lifescan monitors for completeness and accuracy and the results entered into a validated database. the data will be extracted and statistically analysed to determine the accuracy of the arterial blood glucose results obtained using the onetouch veriovue bgms when compared to the arterial blood glucose results obtained on the istat 1 analyser.

Eligibility criteria:
inclusion criteria: age - the potential subject is at least 16 years old. language - subject reads and understands english. informed consent - the potential subject must read the participant information sheet and sign the informed consent form. subject agrees to provide relevant demographic, medical history, and prescription medication information. the subject agrees to allow study staff access to medical records where necessary. the subject agrees to all aspects of the study process, including arterial blood draws performed by an hcp. exclusion criteria: age - subject is under 16 years old. current covid-19 positive test result.
establishment of a pdt patient registry

Conditions: Lung Cancer

Summary: this is a non-intervention patient registry to gather data on the use of photodynamic therapy under real-life conditions. it will involve up to 20 sites in usa.

the purpose of this patient registry is to collect information about a patient's cancer treatment, photodynamic therapy (pdt), used alone or in combination with surgery, chemotherapy and radiotherapy. patients will be registered either before or after pdt is performed, regardless of the indication. analysis of this information may help to refine the treatment care. data collected in the registry includes patient characteristics/demographics, disease characteristics, treatment details (photodynamic therapy, radiation, chemotherapy, surgery, etc.), side effects, and survival outcomes. by participating in this registry, patients will not be asked to do anything that would not ordinarily be done as a matter of routine care including clinical assessments, laboratory tests, radiology procedures, and treatments. information on disease, condition, and treatment will be recorded in the registry during routine visits.

Eligibility criteria:
inclusion criteria: * all adult patients (≥ 18 years of age) treated with pdt. * women and men and members of all races and ethnic groups. * subjects may have received prior treatment for their cancer. * subjects to give a written informed consent for prospectively collected data. exclusion criteria: * none.

Keywords: lung cancer lung carcinoma lung metastases metastases
symptoms and mechanisms of child psychiatric disorders

Conditions: Disruptive Mood Dysregulation Disorder; Attention Deficit Hyperactivity Disorder; Oppositional Defiant Disorder; Severe Irritability; Child Psychiatric Disorders

Summary: in this study the investigators will examine psychiatric symptoms, central neurocognitive functions, parental stress and attachment styles, and biological factors that can give new knowledge about some of the mechanisms present in children referred to outpatient psychiatric clinics. a specific focus will be given to children suffering from severe irritability.

in this study the investigators will examine psychiatric symptoms, central neurocognitive functions, parental stress and attachment styles, and biological factors that can give new knowledge about some of the mechanisms present in children referred to outpatient psychiatric service. a specific focus will be given to children suffering from severe irritability making problems at home, in school, and/or with peers. disruptive mood dysregulation disorder (dmdd) is characterized by chronic and severe irritability and anger in children. dmdd understood as severe or clinical irritability can be regarded as laying above a certain threshold on a irritability continuum. due to dmdd being a relatively new and debated diagnosis there is an urgent need to gain better understanding of the underlying mechanisms of severe irritability in children. this study will explore emotion and behavior symptoms, neuropsychological functions (including social perception), perceived parental stress and attachment styles, and cortisol levels of children and their mothers, in children referred to outpatient psychiatric service including children with severe irritability. parents of children 6 to 12 years will be informed and asked to participate. the work on severe irritability will be divided into six main areas: 1. severe irritability in a norwegian clinical population: prevalence, comorbidity and associated difficulties 2. social and emotional understanding in severe irritability in children 3. executive function in severe irritability in children 4. stress response in severe irritability in children 5. parental stress and attachment style in parents of severe irritability in children 6. dmdd: an affective or conduct disorder? comparing anxiety and depressive symptoms

Eligibility criteria:
inclusion criteria: * referred to outpatient psychiatric service * intelligence quotient (iq) within normal range * child and parents: good enough understanding of norwegian language to give valid answers in interview and tests. * clarified care situation exclusion criteria: * iq below normal range * child and parents: not good enough understanding of norwegian language to give valid answers in interview and tests * unclarified care situation

Keywords: neuropsychology neurocognition executive function social cognition mentalization affect recognition stress cortisol parental stress attachment behavior symptoms emotion symptoms
analysis of thrombo-embolic complications after endovascular treatment of unruptured intracranial aneurysms

Conditions: Unruptured Intracranial Aneurysms

Summary: endovascular treatment of ruptured and unruptured intracranial aneurysms presents complications, mainly the thrombo-embolic complication. no specific studies have been conducted to study factors associated with the occurrence of thromboembolic complications (symptomatic or not) post endovascular treatment of intracranial aneurysms.

in this multicenter, prospective study, patients with treatment of unruptured intracranial aneurysms will be recruited. the thromboembolic complications will be research using diffusion-weighted mri.

Eligibility criteria:
inclusion criteria: * patient having a programmed endovascular treatment for unruptured intracranial aneurysm * patient older than 18 years * patient consenting to participate to the study * patient enrolled in the national healthcare insurance program exclusion criteria: * patients with contraindications for mri * patients whose clinical condition does not allow sufficient cooperation to the realization of mri * patients with arteriovenous malformation intracranial
multinational observational study to describe diagnostic stage shift in patients with lung cancer using medical records

Conditions: Lung Cancer

Summary: multinational observational study to describe diagnostic stage shift in patients with lung cancer using medical records. increased lung cancer screening programs and increased utilization of other screening modalities such as large increase in community chest radiography referral rates in response to public awareness campaigns, as well as unintentional detections through cardiac ct(computed tomography) angiograms, or screening for coronary disease may help in detecting the disease at earlier curable stages. availability and increased access to novel therapies increase the likelihood of an early-stage diagnosis aiming for improved survival.

this is a multicentric, multinational, observational study to describe the shift in stage at diagnosis of lung cancer over the time- period from baseline year to eos (end of study). the study will be implemented in the astrazeneca international region (ie, non-us, non-european countries). the participating countries and sites will be selected based on the availability and accessibility of secondary data sources such as lung cancer databases or emr (electronic medical records) in the target countries. once countries and databases are selected, the protocol will be adapted for the specific country including details about the patient databases. the study will be conducted in compliance with the local legal, ethical, and regulatory requirements of the selected countries. the study-specific data will be extracted from the databases and recorded using ecrf (electronic case report form). this study does not involve direct recruitment of the patients. aggregated data from the databases for each consecutive year starting from the baseline year until eos, of patients with lung cancer meeting the inclusion criteria will be included in the study.

Eligibility criteria:
inclusion criteria: * adult female and male patients ≥18 years old. * confirmed diagnosis of lung cancer (either cytologically or histologically) exclusion criteria: * patients presenting with recurrent or relapsed lung cancer. * patients with a concomitant cancer at the time of diagnosis of lung cancer, except for nonmetastatic nonmelanoma skin cancers, or in situ or benign neoplasms: a cancer will be considered concomitant if it occurs within 5 years of lung cancer diagnosis.

Keywords: lung cancer aggregate data non small cell lung cancer data extraction early stage locally advanced late stage
phase iiib-iv long-term follow-up study for patients who participated in camms03409

Conditions: Relapsing Remitting Multiple Sclerosis

Summary: primary objective: to evaluate long-term safety of alemtuzumab. secondary objectives: * to evaluate long term efficacy of alemtuzumab. * to evaluate the safety profile of participants who received other disease modifying treatment (dmt) following alemtuzumab treatment. * to evaluate participant-reported quality of life (qol) outcomes and health resource utilization of participant who received alemtuzumab. * to evaluate as needed re-treatment with alemtuzumab and other dmts.

the total duration per participants was up to 5.6 years. as per study investigator discretion, participants can be treated with additional courses of alemtuzumab or any commercialized dmts. all participants who completed camms03409 were allowed into the study, which might include specific vulnerable populations. if the investigator decided to treat a participant with a course of alemtuzumab, appropriate cautionary measures were applied as indicated in the approved labelling, or, in ex-european union countries where lemtrada was not approved, according to the investigator's brochure.

Eligibility criteria:
inclusion criteria: participant had completed at least 48 months of the extension study camms03409. signed written informed consent form. exclusion criteria: participant participating in another investigational interventional study. the above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
the influence of a high intensity physical activity intervention on a selection of health related outcomes: an ecological approach

Conditions: To Assess the Impact of the HIT Intervention on Physiological Responses; To Assess the Role of a Secondary High School as a Setting for Promoting Healthy Eating and PA Behaviours; To Determine the Associations Between CVD Risk Factors at Baseline in 15 - 18 Year Old Youth

Summary: the purpose of this study is to determine whether a high intensity exercise intervention can elicit cardiovascular disease protection in adolescents.


Eligibility criteria:
inclusion criteria: * healthy * 15 - 18 yer old that are capable of performing vigorous exercise exclusion criteria: * any health condition that would prevent them from undertaking vigorous exercise

Keywords: public health biochemistry ecological
a retrospective review of a comprehensive cohort of septic shock: assessment of critical determinants of outcome

Conditions: Septic Shock

Summary: septic shock remains the dominant cause of death in icu's of the developed world with approximately 400,000 cases annually in the us and another 20,000 annually in canada. while many retrospective and prospective reviews of septic shock patients have been undertaken worldwide, many key questions remain unanswered. these questions include the true incidence, associated morbidity and mortality of septic shock in north america, key factors associated with successful management and markers suggesting a high probability of a complicated clinical course. part of the reason for the persistence of these questions, is the fact that previous and ongoing reviews of septic shock and severe sepsis have been either limited in number (typically \<150) or biased by the need to be eligible for specific clinical trials (typically, non-eligible patients have not been followed and had data collected. we propose to examine specific questions within a temporally comprehensive cohort of septic shock patients by review of individual charts using a defined data-extraction template.

objectives * determination of impact of rapidity of implementation of antibiotic therapy, source control (where required) and fluid resuscitation on mortality of septic shock * utility of persistence or increase of vasopressor needs over the 1st 24 hours of shock as a predictor of a complicated icu course (icu duration \> 1 week) or death * assessment of initial biochemical parameters, co-morbidities and new onset organ failure at admission as predictors of a complicated icu course (icu duration \> 1 week) and death data collection: data collection would be performed by a combination of study nurses and 2nd or 3rd year medical students hired for the summer for this research project. research nurses and student will be trained by the principal investigator. a minimum of 10% of the charts will be randomly audited by the principal investigator to ensure appropriate data extraction. this will allow the pi to review and correct any discrepant coding issues and judge specific questions (e.g. appropriateness of antibiotics/presence of effective antibiotics or not). data collection tool: attached. in addition, data in the icu registry includes basic epidemiologic data (age, sex, all pertinent medical/surgical comorbidities/risk factors, etc) as well as all apache ii

Eligibility criteria:
inclusion criteria. * the primary analysis will include all patients admitted to the institution with a final diagnosis of septic shock (including transfers). exclusion criteria: * icu patients who do not have a diagnosis of septic shock * these are the only inclusion/exclusion criteria.
aerobic exercise in persons with multiple sclerosis with restless legs syndrome

Conditions: Multiple Sclerosis

Summary: in this studly, the effects of an 12-week aerobic exercise training in persons with multiple sclerosis with restless legs syndrome will be investigated.


Eligibility criteria:
inclusion criteria: * a relapsing-remitting or secondary progressive type of multiple sclerosis, * to be willing to participate in the study. exclusion criteria: * another neurological disorder, * orthopedic surgery history including the ankle-foot, knee, hip, or spine, affecting balance, * diagnosed severe cognitive and/or psychiatric impairment, * having congestive heart failure, coronary, cerebrovascular, and pulmonary disease such as copd * having cardiac disease such as hypertension that would be a contraindication to exercise
changes in host gene expression to differentiate between systemic inflammation and infection after major surgery

Conditions: Infections; Sepsis

Summary: changes in host gene expression may provide additional information to diagnose postoperative infection and improve outcome after surgery. this study aims to validate the early diagnostic performance of specific gene signatures for differentiating infection from non-infected sirs or uncomplicated postoperative course in blood sampes of adult patients undergoing major noncardiac surgery.

rationale: differentiation between the systemic inflammatory response syndrome (sirs) and infection after surgery is challenging. consequent diagnostic uncertainty may result in delayed diagnosis and interventions to prevent organ dysfunction or eventually death. changes in host gene expression may provide additional information to diagnose postoperative infection and improve outcome after surgery. objective: to validate the early diagnostic performance of specific gene signatures1 for differentiating infection from non-infected sirs or uncomplicated postoperative course. study design: a prospective observational multicenter study. study population: adult patients undergoing major noncardiac surgery. main study parameters/endpoints: main study parameters are specific gene signatures. main study endpoint is postoperative infection and sirs. nature and extent of the burden and risks associated with participation, benefit and group relatedness: in each patient blood samples will be drawn for analysis on the following time points: after induction for anaesthesia, directly postoperative and on postoperative day 1 - 7. for each sample 2.5 ml of blood is taken. in a total of 9 samples this results in a cumulative volume of 22.5 ml. whenever possible, blood samples will be drawn simultaneously with routine perioperative laboratory testing. in case of admission to the intensive care unit blood samples will be collected using an arterial line. there are no direct risks or benefits for patients included in the study.

Eligibility criteria:
inclusion criteria: * age \>18 years * major noncardiac surgery with infection risk \>20% exclusion criteria: * age \<18 years * emergency surgery * inability to provide informed consent.
effects of common topical glaucoma therapy on optic nerve head blood flow autoregulation during increased arterial blood pressure and artificially elevated intraocular pressure in healthy humans

Conditions: Glaucoma

Summary: background autoregulation is the ability of a vascular bed to maintain blood flow despite changes in perfusion pressure. the existence of an effective autoregulation in the optic nerve circulation has been shown in animals and humans. the exact mechanism behind this autoregulation is still unknown. the motive for the investigation of optic nerve head (onh) blood flow autoregulation is to enhance the understanding of pathologic eye conditions associated with ocular vascular disorders. to clarify the regulatory mechanisms of onh microcirculation is of critical importance to understand the pathophysiology of glaucoma, because there is evidence that glaucoma is associated with optic nerve head ischemia. several studies indicate that a disturbed autoregulation might contribute to glaucomatous optic neuropathy. currently, five classes of intraocular pressure (iop) reducing drugs are available for topical therapy in patients with glaucoma or elevated intraocular pressure. these drugs have also vasoactive properties, which may influence both the resting ocular circulation and the autoregulatory mechanisms of blood flow during changes in ocular perfusion pressure. study objective to investigate the influence of common topical glaucoma therapy on onh blood flow regulation during changes in iop and systemic arterial blood pressure.


Eligibility criteria:
inclusion criteria: * men aged between 19 and 35 years, nonsmokers * body mass index between 15th and 85th percentile * normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant * normal ophthalmic findings, ametropia \< 1 dpt. exclusion criteria: * regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study * treatment in the previous 3 weeks with any drug * symptoms of a clinically relevant illness in the 3 weeks before the first study day * blood donation during the previous 3 weeks * presence of intraocular pathology: ocular hypertension, glaucoma, retinal vasculopathy or other retinal diseases

Keywords: ocular physiology brimonidine timoptic dorzolamide ocular blood flow regional blood flow